Avita Medical Appendix 4E Year Ending 30 June 2013

/in

Avita Medical ASX announcement link here.

Read more

Alchemia Announces Results For FY 2013 and Progress Across Its Major Assets

/in

Alchemia Announcement link here. • Net profit share from fondaparinux of A$9.6m (US$9.5m) for the financial year • Annual loss for the year of A$4.8m, compared with A$15.1m for the previous year • Cash and receivables at 30 June 2013 of A$25.3m • Phase III trial of HA Irinotecan fully recruited • Collaboration with Merck Serono […]

Read more

Pharmaxis Announces Delay to French Pricing for Bronchitol

/in

Pharmaxis press release link here. Pharmaceutical company Pharmaxis (ASX:PXS) today announced it will scale back resources and investments dedicated to the launch of Bronchitol in France due to delays in reaching an agreement with French authorities on a reimbursed price for the cystic fibrosis treatment. Pharmaxis CEO Mr Gary Phillips said, “Negotiations with the French Healthcare […]

Read more

Australian Medical Media Release: Simplified PBS Listing for Bronchitol (Pharmaxis)

/in

Pharmaxis press release link here. The Australian government has approved a new, simplified Pharmaceutical Benefits Scheme (PBS) status for Bronchitol in the treatment of cystic fibrosis (CF). Following the successful Pharmaxis application to the Pharmaceutical Benefits Advisory Committee (PBAC) and discussions with the Department of Health and Ageing, the new Bronchitol PBS listing removes the restrictive […]

Read more

Alchemia ASX Announcement – Fondaparinux Investor Update and Quarterly Profit Share

/in

Alchemia ASX announcements. Fondaparinux Quarterly Profit Share and Fondaparinux Investor Update.

Read more

Biota Pharmaceuticals Announces Changes to Its Board of Directors

/in

Biota Pharmaceuticals press release link here. ATLANTA, Aug. 19, 2013 (GLOBE NEWSWIRE) — Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (“Biota” or the “Company”), a biopharmaceutical company focused on the discovery and development of anti-infective products to prevent and treat serious and potentially life-threatening infectious diseases, today announced changes to its Board of Directors, including the resignation of Dr. Jeffrey […]

Read more

AmpliPhi Presents Data on Bacteriophages in the Treatment of Lung Infections in Cystic Fibrosis

/in

AmpliPhi press release link here. Data presented at the 20th Biennial Evergreen International Phage Meeting, 4-9 August 2013, Evergreen State College, Olympia, WA, USA RICHMOND, Va. & SYDNEY & LONDON–(BUSINESS WIRE)–Aug. 8, 2013– AmpliPhi BioSciences Corp. (OTC: APHB) (“AmpliPhi”), the leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant bacterial infections, yesterday presented data relating to the use of bacteriophages in the […]

Read more